Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company...
SAN DIEGO, CA / ACCESSWIRE / September 20, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare...
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive...
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver...
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant,...
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused...
THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical...
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age...
OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization...
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old...
Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed...
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to...
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase...
Prof. Carl Wittwer Appointed in inbiome's Advisory Board Amsterdam, The Netherlands, September 20, 2024. Inbiome, a pioneer in advanced molecular diagnostics,...
WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal...
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE20 SEPTEMBER 2024 at 9.30...
Publication concerning a transparency notification(article 14, first paragraph of the law of 2 May 2007 concerning the publication of significant...
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten...